Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.37 |
| ▸ | TACR1 | P25103 | 3/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6774385 | 0.87 | SLC6A2 (0.41) | SLC6A4SLC6A2SLC6A3HTR1A | |
| Hydrochloric Acid SCHEMBL9041147 | 0.85 | SLC6A2 (0.40) | SLC6A4SLC6A2SLC6A3HTR1A | |
| SCHEMBL20002871 | 0.77 | HTR6 (0.36) | SLC6A4TACR1SLC6A2SLC6A3HTR1A | |
| SCHEMBL10795562 | 0.73 | SLC18A3 (0.45) | KDM1ASLC6A4SLC6A2SLC6A3HTR1A | |
| SCHEMBL4771696 | 0.73 | HSD11B1 (0.33) | DPP4DPP9DPP7 | |
| Trifluoroacetic Acid SCHEMBL252584 | 0.72 | MEN1 (0.56) | — | |
| Maleic Acid SCHEMBL10794704 | 0.72 | HRH1 (0.43) | SLC6A4SLC6A2SLC6A3 | |
| Fumaric Acid SCHEMBL10794721 | 0.72 | HRH1 (0.43) | SLC6A4SLC6A2SLC6A3 | |
| Trifluoroacetic Acid SCHEMBL5764625 | 0.72 | HSD11B1 (0.40) | PRCPSLC6A4SLC6A2SLC6A3CACNA1B | |
| SCHEMBL5214386 | 0.71 | SLC6A4 (0.33) | KDM1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348324-B2 | Cyclic amine compounds as CCR5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-03-25 | — | — | US | disclosed |
| EP-1886994-A1 | Cyclic amine compounds as CCR5 antagonists | Takeda Pharmaceutical Company Limited (JP) | 2008-02-13 | — | — | EP | disclosed |
| US-20030114443-A1 | Cyclic amine compounds as CCR5 antagonists | TOBIRA THERAPEUTICS, INC. | 2003-06-19 | — | — | US | disclosed |
| US-6562978-B1 | N-(3-(4-(4-(Aminocarbonyl)benzyl)-1-piperidinyl)propyl)-N-(3, 4-dichlorophenyl)-1-(methylsulfonyl)-4-piperidinecarboxamide or a salt thereof for treatment of AIDS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-05-13 | — | — | US | disclosed |
| CN-1390201-A | cyclic amine compounds as CCR5 antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-01-08 | — | — | CN | disclosed |
| EP-1220842-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2002-07-10 | — | — | EP | disclosed |
| WO-2001025200-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114443-A1 | Cyclic amine compounds as CCR5 antagonists | CCR5, CCR1, CCR3 | PRCP 4385/4885KDM1A 2609/4885SLC6A4 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.